We report a simple, enzymatic method for determining angiotensin-converting enzyme (ACE; EC 3.4.15.1) in serum. The proposed method features coupling an established reaction catalyzed by y-glutamyltransferase (GGT; EC 2.3.2.2) to the ACE reaction, which releases glycylglycine from the artificial substrate hippuryl-glycyl-glycine. The glycyl-glycine released by the ACE reaction becomes rate-limiting in the GGT reaction, in which it participates as a receptor substrate for a y-glutamyl group transferred from a donor substrate, L-'y-glutamyl-3-carboxy-4-nitroanhlide.The reaction releases 3-carboxy-4-nitroaniline, which is monitored spectrophotometncallyat 410 nm. The resulting rate of change inabsorbance islinearly related to the glycyl-glycine concentration and therefore to the activity ofACE. The linear rangeofthe method extends from ACE values <50 to at least 1300 U/L of serum. Good precision is indicated by a low CV for replicate analyses (3.6% and 4.6% forwithin-run and day-to-day assays, respectively, fornormalACE activity, and 3.1% within-run forhigh ACE activity). Resultsalsocorrelate wellwith thoseofan established colonmetric method (r = 0.978).
associated with microangiopathy (4) . The clinical diagnostic potential of ACE has prompted renewed efforts to develop clinically applicable methods to determine it.
Among the reported methods for determining serum ACE, most are based on the enzyme's ability to hydrolyze the artificial substrates hippuryl-histidyl-leucine or hippuryl-glycyl-glycine (Hip-Gly-Gly), producing hippunc acid and the dipeptides histidyl-leucine or glycylglycine (Gly-Gly), respectively. A wide range of analytical methods have been proposed for measuring either the dipeptides or hippuric acid after the hydrolysis. All of these methods, however, have one or more of the following disadvantages: the need for product extraction with organic solvents (1, 5, 6) Hip-Gly-Gly ± hippuric acid + Gly-Gly Gly-Gly + GOCN 22 y-glutamyl-glycylglycine +
3-carboxy-4-nitroaniline

Materials and Methods
Apparatus
For all kinetic absonbance measurements, we used an ultraviolet--visible scanning spectrophotometer (Model UV21O1PC; Shimadzu Corp., Columbia, MD).
Specimens
Serum samples, screened for bloodborne infectious disease, were obtained from volunteer blood donors at a local Red Cross center and from an outpatient clinic at a local hospital. Samples were stored at -25 #{176}C and were assayed within 2 weeks after collection.
Reagents
Hip-Gly-Gly, 4 -(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), GGCN, GOT, and Gly-Gly were all purchased from Sigma Chemical Co. (St. Louis, MO).
Buffered ACE substrate.
This buffer was prepared according to the method of Neels et al. (7) . Briefly, 0.238 g of HEPES (50 nunol/L), 0.351 g of NaC1 (300 mmol/L), 1 .136 g of Na2504 (400 mmolIL), and 0.179 g of Hip-GlyGly (30 mmol/L) were dissolved in 15 mL of distilled water. We then added 50 L of saturated NaOH. The pH was adjusted to 8.0 with NaOH, and the volume brought to 20 mL with distilled water. The buffered substrate must be stored frozen until used, and once thawed cannot be subjected to another freeze-thaw cycle.
Serum blank buffer. This was prepared exactly as the buffered ACE substrate was, except that Hip-Gly-Gly was omitted.
HEPES/saline
buffer. This buffer, also 50 mmol/L HEPES, was prepared in 150 mmoIJL NaC1 only and adjusted to pH 7.9. It was used to prepare solutions of GOT, GGCN, and Gly-Gly standards.
A 20 kUIL stock solution of GOT was prepared by stored at -25 #{176}C. All solutions used in the GOT reaction were allowed to equilibrate to ambient temperature before the reaction.
Procedures
Samples.
In a 1.5-mL conical centrifuge tube, incubate 10 pL of serum and 100 L of the buffered ACE substrate solution at 37#{176}C for 30 mm. Add 850 L of 1.0 mmoIJL GGCN solution to stop the ACE reaction and to introduce the donor substrate for the GOT reaction. Allow the tube to equilibrate to ambient temperature (10-15 miii). Add to the tube 50 uL (-0.33 U) of working GOT solution, mix well, and transfer to a semimicro cuvet. Record the spectrophotometnic change in absorbance over a 2-mm Gly-Gly standards. To 100 pL of serum blank buffer and 10 pL of Gly-Gly standard solution in a 1.5-mL centrifuge tube, add 850 pL of GGCN solution followed by 50 zL of GOT solution. Mix, transfer to a semimicro cuvet, and record #{163}4/2 miii.
Calculations.
Because 1 U of ACE activity is defined as the amount of enzyme required to release 1.0 pmol of hippuric acid (and therefore Gly-Gly) per minute per liter of serum, the units can be equated to Gly-Gly concentrations as described by Neels et al. 
where #{163}4/2 miii of S, SB, Std, and AT refer to absorbance increments of the sample, serum blank, standard (10 mmol/L), and autotransfer reactions, respectively. The comparison method was carried out as described (7). The procedure for the release of Gly-Gly from Hip-Gly-Gly is exactly the same as that of our proposed rate-limiting. It was therefore necessary to identify a suitable concentration of the donor substrate (GGCN) and an activity of GOT that yielded reaction rates that correlate directly with Gly-Gly concentrations.
The autotransfer (reagent blank) reaction. In addition to the reaction between Gly-Gly and GGCN, GOT also catalyzes an autotransfer reaction, in which GOCN acts as both donor and receptor substrate.
The autotransfer reaction is also accompanied by the release of chromophore (13) . The rate of the reaction, measured as the increase in absorbance during the 2-mm test period, is 
GGCN substrate.
At high ratios of concentrations of donor substrate (GGCN) to acceptor substrate (Gly-Gly), the desired transfer reaction involving the two substrates is reduced because of the displacement of the much more efficient acceptor substrate from the accep- 
GGCN(1.0 mmol/L)and various concentrations of Gly-Gly
Concentrations of Gty-GIystandards,expressedin moU1O pL. are indicated to the rhtof the absothance lines with which they correspond. The autotransfor (AT) reaction occurs in the absence of Gly-Gly tor site of the enzyme (14). With Gly-Gly being ratelimiting in our system, the concentration of GGCN used must be sufficiently low so as not to be inhibitory to the receptor, yet high enough that linearity is not compromised by substrate depletion during the 2-mn reaction time. We found the concentration of 1.0 mmol/L quite suitable, providing excellent linearity throughout a wide range of Gly-Gly concentrations.
GGT. Because the slope of the absorbance line is very sensitive to differences in the concentration of the transferase, the system requires careful attention to its concentration. Low slopes resulting from too low a concentration of enzyme reduces analytical sensitivity, whereas inappropriately high concentrations cause excessive substrate depletion and the accompanying deviation from linearity. Our stating the use of 0.33 U of enzyme per test is based on the supplier's advertised content of 100 U/vial, and is therefore only an approximation. We found that a working solution of the enzyme that yields a #{163}4/2 mm of between 0.05 and 0.09 for the autotransfer reaction is most suitable. In our study, this was achieved by reconstituting 100 U in 5.0 mL of buffer (20 U/mL stock solution) and diluting threefold (to 6.7 U/mL) for the working reagent.
Temperature.
After incubating the samples and serum blanks at 37 #{176}C, we let them, along with standards and all reagents, equilibrate to ambient temperature (23 #{176}C in our laboratory). Small between-assay fluctuations in temperature are tolerated in the method because the rates of the autotransfer and standard reactions are affected similarly to the rates of the samples. It is important, however, to maintain a constant withinassay temperature.
Method Evaluation
Calibration. Figure   2 shows a calibration curve, constructed as a regression line between reaction rates (E&A/2miii) and Gly-Gly content, moIJ10 L (along with the corresponding ACE activity units). The highest serum ACE activity, such as that associated with active sarcoidosis, rarely exceeds 1000 UIL (7). Because calibration is linear even through ACE values >1300 U/L, it should not be necessary to dilute the specimens.
Precision.
Within-run
precision studies were performed on both normal and high ACE activity serum (n = 14 each), and a day-to-day precision study was carried out on another normal serum (n = 9). The following data were obtained: within-run, normal ACE 1, mean = 317 U/L, SD = 11.6 U/L, CV = 3.6%; within-run, high ACE, mean = 886 U/L, SD = 27.6 U/L, CV = 3.1%; day-today, normal ACE 2, mean = 274 UIL, SD = 12.7 U/L, CV = 4.6%.
Recovery/accuracy. A standard solution of ACE and two different sera were analyzed for ACE by our method. The standard was then combined in equal amounts with each of the serum samples, and the combinations were reassayed. Recoveries were 95% and 99% of the predicted values. Reference interval. The mean ACE activity among the 30 blood bank donors was found by our method to be 285 (SD 76) U/L. These values are similar to those of 281 sample population.
Comments
Serum blank absorbance changes must be subtracted from sample values to maximize accuracy and precision. We found, however, that the contribution of the blanks was rather constant regardless of the amount of ACE activity.
Our mean serum blank value for all sera tested was equivalent to 0.016 mol of Gly-Gly per 10-jtL samples (53.3 UIL ACE); values ranged from 28 to 76 UIL ACE equivalents. These values represent -10-25% of normal serum ACE activity. Although the source of the serum blank activity has not been defined, it is unlikely to be attributable to endogenous GOT activity, because no increase in absorbance occurs when GGCN substrate alone is added to the incubated serum. Furthermore, the activity is temperature-independent, as
shown by the observation that it remained the same whether the serum was incubated at 37 or 23#{176}C for 30 mm. We think that the presence of an alternative receptor substrate for GOT, the concentration of which does not vary significantly among sera, may be the contributing factor.
The addition of GGCN to the incubated sample, as described in the procedure, effectively stops further ACE activity. This was demonstrated by an experiment in which we added GGCN to replicate, incubated serum samples, followed at 30-min intervals by adding GOT sequentially to each of the samples of the series, and measuring the absorbance change. Over a period of 3 h, we observed no difference in the absorbance change among the samples afLer adding the enzyme, which suggests that no additional Gly-Gly had been released during that time.
The contribution of endogenous GOT is insignificant under the conditions of the assay. This was confirmed experimentally by the observation that, among all sera tested, there was never an increase in absorbance after adding the GOCN to the incubated sera before adding the GOT reagent. This is because our system requires a much higher concentration of reagent enzyme (-1300-fold) than that contributed by endogenous enzyme contained in the small sample. Allowing for even a 10-fold increase in endogenous GOT, as could occur in intrahepatic cholestasis (15), the contribution would not be significant.
Timing of the GOT reaction should begin within 15-30 s from the time the enzyme is added because deviation from linearity begins to occur beyond 3-4 miii, especially at high Gly-Gly concentrations. Our spectrophotometer is equipped with an "auto-zero" feature that we activate, followed immediately by "start." We set the time course to stop at 2 mm automatically.
For less sophisticated instruments, manual timing of displayed absorbance is quite satisfactory.
A 2-or 3-min time course for the kinetic reaction is recommended because of the assurance of linearity through this time period. Shorter timing periods are more subject to timing errors and to spectral error from low absorbances. 
